Table 3.
Toxicity results concerning the 44 DEBIRI treatments
| Toxicity (% out of 44 treatments) | G1
|
G2
|
G3
|
G4
|
||||
|---|---|---|---|---|---|---|---|---|
| 100 mg | 200 mg | 100 mg | 200 mg | 100 mg | 200 mg | 100 mg | 200 mg | |
| Pain | 6% | 7% | 3% | 4% | 1% | 1% | 0% | 0% |
| Hypertension | 9% | 10% | 5% | 6% | 0% | 0% | 0% | 0% |
| Vomiting | 2% | 3% | 0% | 2% | 0% | 0% | 0% | 0% |
| Nausea | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Diarrhea | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% |
| Asthenia | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Leukopenia | 3% | 4% | 3% | 4% | 0% | 0% | 0% | 0% |
| Anemia | 3% | 3% | 2% | 3% | 0% | 0% | 0% | 0% |
| Fever | 8% | 8% | 0% | 0% | 0% | 0% | 0% | 0% |
| Alopecia | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Hypertransaminasemia (AST) | 11% | 12% | 11% | 12% | 11% | 12% | 0% | 2% |
| Hypertransaminasemia (ALT) | 15% | 15% | 8% | 10% | 8% | 8% | 0% | 2% |
Abbreviations: DEBIRI, drug-eluting beads with irinotecan; AST, aspartate aminotransferase; ALT, alanine aminotransferase.